Market Overview
Global HIV medicines market size was valued at USD 32.8 billion in 2024 and is projected to reach USD 45.6 billion by 2032, exhibiting a CAGR of 4.2% during the forecast period.
This growth is driven by increasing HIV prevalence, improved access to treatment in developing regions, and ongoing innovations in antiretroviral therapy (ART).
HIV medicines include antiretroviral drugs that suppress viral replication and slow disease progression. These medications fall into seven classes: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), entry inhibitors, pharmacokinetic enhancers, and combination drugs. Combination therapies account for over 60% of market share due to their higher efficacy in viral suppression.
Market size
USD 32.8 billion in 2024
USD 45.6 billion by 2032
of 4.2%
Fixed-Dose Combination (FDC) Segment Dominates Due to Improved Patient
Compliance and Efficacy
The market is segmented based on type into:
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Protease Inhibitors (PIs)
Integrase Strand Transfer Inhibitors (INSTIs)
Fixed-Dose Combinations (FDCs)
By Application
Treatment Segment Leads Due to Increasing HIV Prevalence and Treatment Adoption
The market is segmented based on application into:
Treatment Prevention (PrEP)
Pediatric care
Post-exposure prophylaxis
Portable Neuromonitoring Device Market
Our Key Players
Gilead Sciences, Inc. (U.S.)
ViiV Healthcare (U.K.)
Merck & Co., Inc. (U.S.)
Biocon Limited (India)
Johnson & Johnson (Janssen) (U.S.)
Flamingo Pharmaceuticals Limited (India)
IPCA Laboratories Ltd. (India)
https://www.24lifesciences.com
